Sanofi is investing in its more buoyant businesses like rare diseases and making a further push in the cancer market, snapping up U.S. biotechnology firm Synthorx in a cash deal worth about $2.5 …
More UPDATE 1-Sanofi shares rally on new margin goals, narrow drug focus Videos